Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

MaxCyte, Inc

Contributing Author

Recent Articles by MaxCyte, Inc

Aug-19
MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies MXCT +9.45% GlobeNewswire
Aug-12
MaxCyte Reports Second Quarter 2026 Financial Results MXCT MXCT +9.45% GlobeNewswire
Jul-21
MaxCyte Announces Multi-Platform Technology License Partnership with Genentech to Advance Cell Therapy Development MXCT +5.13% GlobeNewswire
Jul-15
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 MXCT GlobeNewswire
May-12
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance MXCT MXCT +24.06% GlobeNewswire
Apr-29
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 MXCT -6.78% MXCT +7.63% GlobeNewswire
Mar-31
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MXCT MXCT +5.92% GlobeNewswire
Mar-24
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance MXCT MXCT -6.81% GlobeNewswire
Mar-23
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer MXCT GlobeNewswire
Feb-24
MaxCyte unveils ExPERT DTx, a 96-well electroporation platform to accelerate discovery MXCT +5.01% GlobeNewswire
Feb-23
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 MXCT GlobeNewswire
Jan-12
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results MXCT GlobeNewswire
Nov-12
MaxCyte Announces Planned CFO Transition in 2026 MXCT GlobeNewswire
Nov-12
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Nov-05
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Oct-08
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 MXCT +9.68% GlobeNewswire
Oct-06
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors MXCT GlobeNewswire
Sep-22
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability MXCT MXCT +10.32% GlobeNewswire
Aug-06
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance MXCT MXCT -29.90% GlobeNewswire
Aug-04
MaxCyte Signs Platform License Agreement with Adicet Bio MXCT GlobeNewswire
Jul-31
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline MXCT GlobeNewswire
Jul-09
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 MXCT GlobeNewswire
Jun-11
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies MXCT GlobeNewswire
May-07
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT MXCT -11.31% GlobeNewswire
May-07
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT MXCT -11.31% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)